Repligen Corp. Stock
Repligen Corp. Stock
Repligen Corp. gained 0.670% compared to yesterday.
Repligen Corp. is currently one of the favorites of our community with 12 Buy predictions and no Sell predictions.
As a result the target price of 182 € shows a slightly positive potential of 15.45% compared to the current price of 157.65 € for Repligen Corp..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Repligen Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Repligen Corp. in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Cons
?
B****
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Repligen Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Repligen Corp. | 0.670% | -2.308% | -10.206% | -4.162% | -6.563% | -12.293% | - |
| Opko Health Inc. | -4.740% | -9.665% | 40.295% | -13.528% | -18.540% | -67.863% | -46.034% |
| Catalent Inc. | -0.830% | 1.053% | 2.485% | 25.219% | 28.107% | -43.247% | 53.698% |
| Amicus Therapeutics Inc. | -2.860% | -4.717% | -5.607% | -1.942% | -24.060% | 20.958% | - |
Comments
Repligen Co. (NASDAQ: RGEN) had its price target raised by analysts at Stifel Nicolaus from $165.00 to $207.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target raised by analysts at KeyCorp from $210.00 to $220.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target raised by analysts at JPMorgan Chase & Co. from $170.00 to $210.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat